rly-4008
relay therapeutics,delcath systems
['focus trial', 'rly-4008', 'refocus']
#esmo2022 refocus trial ifgfr2 inhibition (rly-4008) in cca w/ fgfr2 f/r
showing exciting rr and a different tox profile compared to other ifgfr! rly-4008 also seems to be active against some resistance mutations... 
Maria Cecília Mathias - Medical Oncologist and GI Fellow @grupoOncoclínicas ?? Former Oncology Fellow @ ICESP  | ?? Baiana ??????and proud of it! ????